Characterization of a Form of Bovine Factor VIII Which Does Not Aggregate Human Platelets

Summary

Fractionation of partially purified bovine factor VIII on tricalcium citrate columns produces a material which contains high levels of factor VIII procoagulant activity and factor VIII- related antigen, but does not aggregate human platelets. The procoagulant activity can be blocked by human inhibitors of factor VIII: C and by rabbit antibody to bovine factor VIII. Its activity can be increased by thrombin modification. The apparent molecular weight of this form of factor VIII is significantly lower than that of the forms of factor VIII which contain platelet aggregating activity, and it exhibits a higher mobility on agarose electrophoresis.

Keywords

Factor VIII - Bovine - Platelet aggregation - von Willebrand factor

• References

• 1 Forbes CD, Prentice CR M. Aggregation of human platelets by purified porcine and bovine antihemophilic factor. Nature, New Biology 1973; 241: 149-150
• 2 Weiss HJ, Rogers J, Brand H. Defective ristocetin-induced platelet aggregation in von Willebrand’s disease and its correction by Factor VIII. J Clin Invest 1973; 52: 2697-2707
• 3 Solum NO. Aggregation of human platelets by bovine platelet fibrinogen. Scand J Haematol 1968; 5: 474-485
• 4 Allain JP, Cooper HA, Wagner RH, Brinkhous KM. Platelets fixed with paraformaldehyde: A new reagent for assay of von Willebrand factor and platelet aggregating factor. J Lab Clin Med 1975; 85: 318-328
• 5 Kirby EP, Mills DC B. The interaction of bovine Factor VIII with human platelets. J Clin Invest 1975; 56: 491-502
• 6 Legaz ME, Weinstein MJ, Hildebrant CM, Davie EW. Isolation, subunit structure, and proteolytic modification of bovine Factor VIII. Ann NY Acad Sci 1975; 240: 43-61
• 7 McKee PA, Andersen JC, Switzer ME. Molecular structural studies of human factor VIII. Ann NY Acad Sci 1975; 240: 8-33
• 8 Griggs TR, Cooper HA, Webster WP, Wagner RH, Brinkhous KM. Plasma aggregating factor (bovine) for human platelets: A marker for study of antihemophilic and von Willebrand factors. Proc Nat Acad Sci (US) 1973; 70: 2814-2818
• 9 Vehar GA, Davie EW. Preparation and Properties of Bovine Factor VIII (Antihemophilic Factor). Biochem 1980; 19: 401-410
• 10 Zimmerman TS, Roberts J, Edgington TS. Factor VIII-related antigen: Multiple molecular forms in human plasma. Proc Nat Acad Sci (US) 1975; 72: 5121-5125
• 11 Over J, Bouma BM, van Mourik JA, Sixma JJ, Vlooswijk R, Bakker-Woudenberg I. Heterogeneity of human Factor VIII. I. Characterization of Factor VIII present in the supernatant of cryo-precipitate. J Lab Clin Med 1978; 91: 32-46
• 12 Schmer G, Kirby EP, Teller DC, Davie EW. The isolation and characterization of bovine Factor VIII (anti-hemophilic factor). J Biol Chem 1972; 247: 2512-2521
• 13 March SC, Parikh I, Cuatrecases P. A simplified method for cyanogen bromide activation of agarose for affinity chromatography. Anal Biochem 1974; 60: 149-152
• 14 Proctor RR, Rapaport SI. The partial thromboplastin time with kaolin. A simple screening test for first stage plasma clotting factor deficiencies Amer J Clin Pathol 1961; 36: 212-219
• 15 Bouma BN, Starkenburg AF. Dilution of haemophilic plasma used as a reagent in the determination of anti-haemophilic factor A (Factor VIII). Haemostasis 1974; 3: 94-97
• 16 Zimmerman TS, Ratnoff OD, Powell AF. Immunologic differentiation of classic hemophilia (Factor VIII deficiency) and von Willebrand’s disease. J Clin Invest 1971; 50: 244-254
• 17 Laurell C-B. Antigen-antibody crossed electrophoresis. Anal Biochem 1965; 10: 358-361
• 18 Zimmerman TS, Abilgaard CF, Edgington TS. Multiple molecular forms of Factor VIII-related antigen in normal plasma: Relationship to molecular abnormalities in von Willebrand’s disease. Clin Res 1976; 24: 44A
• 19 Doucet-de Bruine MH M, Sixma JJ, Over J, Besser-Visser NH. Heterogeneity of human Factor VIII. II. Characterization of forms of Factor VIII binding to platelets in the presence of ristocetin. J Lab Clin Med 1978; 92: 76-107
• 20 Brown JW, Baugh R, Hougie C. Selective destruction of the platelet aggregating component in bovine Factor VIII preparations by reduction. Thromb Res 1976; 8: 777-783
• 21 Cooper HA, Barnes DS, Wagner RH. Dithiothreitol reduction of bovine platelet aggregating factor (PAF). Blood 1975; 46: 1048 (abstract)
• 22 Counts RB, Paskell SL, Elgee SK. Disulfide bonds and the quaternary structure of Factor VIII/von Willebrand Factor. J Clin Invest 1978; 61: 702-709
• 23 Andersen JC, Switzer ME, McKee PA. Support of Ristocetin-Induced Platelet Aggregation by Procoagulant-Inactive and Plasmin- Cleaved Forms of Human Factor/von Willebrand Factor. Blood 1980; 55: 101-108
• 24 Atichartakam V, Marder VJ, Kirby EP, Budzynski AZ. Effects of enzymic degradation on the subunit composition and biologic properties of human Factor VIII. Blood 1978; 51: 281-297
• 25 Kirby EP, Martin N, Marder VJ. Degradation of bovine Factor VIII by plasmin and trypsin. Blood 1974; 43: 629-640
• 26 Guisasola JA, Cockbum CG, Hardisty RM. Plasmin Digestion of Factor VIII: Characterization of the Breakdown Products with Respect to Antigenicity and von Willebrand Activity. Thromb Haemostas 1978; 40: 302-315
• 27 Martin SW, Marder VJ, Francis CW, Loftus LS, Barlow GH. Enzymatic degradation of the Factor VIII-von Willebrand Protein: A unique tryptic fragment with ristocetin cofactor activity. Blood 1980; 55: 847-858
• 28 Hughes R. Effect of pH on the Platelet Aggregating Factor in Porcine Factor VIII Concentrates. Thromb Haemostas 1980; 43: 66